← All trials
NCT03175731
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2017
- Primary completion
- Jun 30, 2020
- Completion date
- Jun 30, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Qilu Hospital of Shandong UniversityLead sponsor
- Qingdao UniversityCollaborator
- Shandong UniversityOverall official - principal investigator
- Shandong UniversitySponsor investigator
- Linyi People's HospitalCollaborator
- Zibo City First HospitalCollaborator
- Jining NO.1 People 's HospitalCollaborator
- Second People 's Hospital of LiaochengCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.